China-based MicroPort Scientific Corp’s (HKG: 0853) spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has announced receiving marketing approval in Thailand for its in-house developed next-generation transcatheter aortic valve implantation (TAVI) product, the VitaFlow Liberty transcatheter aortic valve implantation system, and the Alwide Plus balloon catheter. This approval expands the company’s market reach and enhances its global presence.
Product Approvals and Market Expansion
VitaFlow Liberty, which was approved for marketing in China in August 2021, is awaiting regulatory decisions in Europe. The product has already obtained market approvals in Argentina in December 2021 and Colombia in August 2022. Alwide Plus, an upgraded version of MicroPort CardioFlow’s Alwide balloon catheter, received marketing approval in China in July 2021. These approvals highlight the company’s commitment to bringing innovative and effective solutions to the global market.
Product Features and Benefits
Alwide Plus significantly improves puncture resistance and enhances the sheath design at the end of the catheter. This design improvement allows for a better sense of use and increased safety during balloon expansion operations. The product’s advanced features are expected to enhance procedural outcomes and patient safety.
Strategic Implications
The marketing approval of VitaFlow Liberty and Alwide Plus in Thailand is a strategic achievement for MicroPort CardioFlow Medtech. It underscores the company’s dedication to advancing cardiovascular treatments and expanding its product portfolio globally. By securing approvals in multiple markets, MicroPort aims to improve access to high-quality medical devices and contribute to the broader goal of enhancing patient care.-Fineline Info & Tech
